{
  "Johnson & Johnson": {
    "2023": {
      "FORM": "8-K",
      "CATEGORIES": {
        "Section 5 - Corporate Governance and Management": {
          "ITEMS": {
            "Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers": {
              "content": "Upon the closing of the initial public offering of Kenvue Inc., Thibaut Mongon will cease to be Executive Vice President, Worldwide Chairman, Consumer Health and member of the Executive Committee of Johnson & Johnson and will continue his role as Chief Executive Officer of Kenvue Inc.",
              "subsections": {}
            },
            "Item 5.07 - Submission of Matters to a Vote of Security Holders": {
              "content": "The 2023 Annual Meeting of Shareholders of Johnson & Johnson (the “Company”) was held on April 27, 2023. The shareholders voted on six items.",
              "subsections": {
                "Summary of Voting Results": "At the 2023 Annual Meeting of Shareholders, the shareholders:\n• Elected all 12 Director nominees named in the 2023 Proxy Statement.\n• Approved, on an advisory basis, the executive compensation philosophy, policies and procedures.\n• Approved, on an advisory basis, having an advisory vote on executive compensation every one (1) year.\n• Ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2023.\n• Did not approve the shareholder proposal for a Vaccine Pricing Report.\n• Did not approve the shareholder proposal for a report on the Impact of Extended Patent Exclusivities on Product Access.",
                "1. Election of Directors": "The following are the final voting results for the election of directors:\n- D. Adamczyk: For 1,786,272,387; Against 16,426,067; Abstain 16,974,577; Non-Votes 353,172,322\n- M. C. Beckerle: For 1,789,457,274; Against 13,764,941; Abstain 16,450,816; Non-Votes 353,172,322\n- D. S. Davis: For 1,756,303,275; Against 46,470,790; Abstain 16,898,966; Non-Votes 353,172,322\n- J. A. Doudna: For 1,789,027,330; Against 14,257,035; Abstain 16,388,666; Non-Votes 353,172,322\n- J. Duato: For 1,688,009,715; Against 120,870,955; Abstain 10,792,361; Non-Votes 353,172,322\n- M. A. Hewson: For 1,773,472,628; Against 29,649,436; Abstain 16,550,967; Non-Votes 353,172,322\n- P. A. Johnson: For 1,804,950,345; Against 9,856,598; Abstain 4,866,088; Non-Votes 353,172,322\n- H. Joly: For 1,772,344,027; Against 30,395,092; Abstain 16,933,912; Non-Votes 353,172,322\n- M. B. McClellan: For 1,788,586,733; Against 14,265,282; Abstain 16,821,016; Non-Votes 353,172,322\n- A. M. Mulcahy: For 1,698,043,017; Against 104,917,215; Abstain 16,712,799; Non-Votes 353,172,322\n- M. A. Weinberger: For 1,788,359,732; Against 14,280,263; Abstain 17,033,036; Non-Votes 353,172,322\n- N. Y. West: For 1,793,769,456; Against 9,125,005; Abstain 16,778,570; Non-Votes 353,172,322",
                "2. Advisory Vote to Approve Named Executive Officer Compensation": "For: 1,685,320,654\nAgainst: 123,275,647\nAbstained: 11,076,730\nNon-Votes: 353,172,322",
                "3. Advisory Vote on the Frequency of Voting to Approve Named Executive Officer Compensation": "For 1 Year: 1,785,566,411\nFor 2 Years: 4,955,319\nFor 3 Years: 22,089,730\nAbstained: 7,061,571\nNon-Votes: 353,172,322\nBased on the voting results on this advisory proposal, the Board of Directors has decided that it will include an advisory vote on executive compensation in the Company’s proxy statement every one (1) year until the next required advisory vote on the frequency of such votes, which will occur no later than the Company’s Annual Meeting of Shareholders in 2029.",
                "4. Ratification of Appointment of PricewaterhouseCoopers LLP": "For: 2,048,852,179\nAgainst: 118,621,657\nAbstained: 5,371,517\nNon-Votes: 0",
                "5. Shareholder Proposal - Vaccine Pricing Report": "For: 569,515,836\nAgainst: 1,223,800,230\nAbstained: 26,356,965\nNon-Votes: 353,172,322",
                "6. Shareholder Proposal - Impact of Extended Patent Exclusivities on Product Access": "For: 258,032,003\nAgainst: 1,530,773,877\nAbstained: 30,867,151\nNon-Votes: 353,172,322"
              }
            }
          }
        }
      }
    }
  }
}